Lightbulb icon

EXCEED ET (NCT05482971): a Phase 2b, single-arm, multicenter study designed to evaluate the effectiveness and safety of ropeginterferon alfa-2b-njft in adult patients with essential thrombocythemia (ET).1,2

Ropeginterferon alfa-2b-njft is an investigational therapy that is not yet approved by any regulatory authority for the treatment of ET.1

PharmaEssentia is the sponsor of the EXCEED ET study.1

Now recruiting: Phase 2b1,2

DNA strand graphic